A. Raju | PharmaBiz.com | Hyderabad | 4 May 2013
The clinical trial industry in India is currently facing a challenging time and witnessing a downward trend as investors are looking to shift their focus to other liberal destinations like China, Turkey and Malaysia, says Dr C Raghu, director of Prime Hospitals in Hyderabad.
With the activism of media, judiciary and regulatory bodies, 90 per cent of clinical trial industry in India has slowed down. According to Dr C Raghu, chief cardiologists and director of Prime Hospitals, the clinical trial industry is witnessing a downtrend as investors are shifting their focus to other liberal destinations like China, Turkey and Malaysia.
At present, China is leading the clinical trial industry in the world followed by Turkey and Malaysia. These destinations are having liberal regulatory system and the government is also encouraging the pharmaceutical, biotechnology industries to invent and discover innovative drugs and procedures for treating patients suffering from deadly diseases like cancer and AIDS.